Biotage AB (STU:PQX1) Debt-to-Equity : 0.10 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Biotage AB Debt-to-Equity?

Biotage AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.9 Mil. Biotage AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €32.4 Mil. Biotage AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €343.7 Mil. Biotage AB's debt to equity for the quarter that ended in Mar. 2024 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biotage AB's Debt-to-Equity or its related term are showing as below:

STU:PQX1' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.11 Max: 0.36
Current: 0.1

During the past 13 years, the highest Debt-to-Equity Ratio of Biotage AB was 0.36. The lowest was 0.00. And the median was 0.11.

STU:PQX1's Debt-to-Equity is ranked better than
67.23% of 711 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs STU:PQX1: 0.10

Biotage AB Debt-to-Equity Historical Data

The historical data trend for Biotage AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB Debt-to-Equity Chart

Biotage AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.27

0.16

0.15

0.13

0.07

Biotage AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.13	0.10	0.11	0.07	0.10

Competitive Comparison of Biotage AB's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Biotage AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotage AB's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biotage AB's Debt-to-Equity falls into.

Biotage AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biotage AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.95	+	20.204)	/	326.925
	=	0.07

Biotage AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.916	+	32.43)	/	343.654
	=	0.10

Biotage AB (STU:PQX1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biotage AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biotage AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotage AB (STU:PQX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (STU:PQX1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BIOT:Sweden 0GRP:UK

Address

Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03

Website

https://www.biotage.com

Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB (STU:PQX1) Headlines

No Headlines